On June 1, Innovent Biologics (01801.HK) declined 3.12% in regular trading, trading at HKD 81.05/share, with trading volume of HKD 642 million. The decline comes amid a broad biotech sector correction and emerging concerns over regulatory approval uncertainty surrounding its recently announced Pfizer partnership.

On May 29, Innovent Biologics announced a landmark global strategic licensing and collaboration agreement with Pfizer covering 12 early-stage oncology programs, with a total deal value of up to USD 10.5 billion including a USD 650 million upfront payment and up to USD 9.85 billion in milestone payments. The stock surged over 11% on the announcement day. However, given that the 12 programs are still at early stages and require extensive regulatory approvals across multiple jurisdictions, market participants have begun pricing in execution risk.

The broader biotech sector weighed heavily on sentiment, with BEIGENE down 3.28%, Remegen down 5.08%, and SKB Bio down 3.64%. This systemic selling pressure compounded the post-rally profit-taking in Innovent following its sharp gain last week.

(The above content is based on publicly available market information, generated by a program or algorithm, and is intended solely as a stock movement alert. It does not constitute investment advice or a basis for trading decisions.)